274 related articles for article (PubMed ID: 29390382)
1. Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy: A case report and review of the literature.
Song JC; Ding XL; Sun XH; Safi M; Tian J
Medicine (Baltimore); 2017 Dec; 96(50):e9278. PubMed ID: 29390382
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.
Kluger HM; Chiang V; Mahajan A; Zito CR; Sznol M; Tran T; Weiss SA; Cohen JV; Yu J; Hegde U; Perrotti E; Anderson G; Ralabate A; Kluger Y; Wei W; Goldberg SB; Jilaveanu LB
J Clin Oncol; 2019 Jan; 37(1):52-60. PubMed ID: 30407895
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report.
Lepir T; Zaghouani M; Roche SP; Li YY; Suarez M; Irias MJ; Savaraj N
Medicine (Baltimore); 2019 Jan; 98(2):e13804. PubMed ID: 30633154
[TBL] [Abstract][Full Text] [Related]
4. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
Afzal MZ; Shirai K
J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
[TBL] [Abstract][Full Text] [Related]
6. The use of pembrolizumab for the treatment of metastatic uveal melanoma.
Kottschade LA; McWilliams RR; Markovic SN; Block MS; Villasboas Bisneto J; Pham AQ; Esplin BL; Dronca RS
Melanoma Res; 2016 Jun; 26(3):300-3. PubMed ID: 26848796
[TBL] [Abstract][Full Text] [Related]
7. Hypophysitis secondary to pembrolizumab: a case report and review of the literature.
Montero Pérez O; Sánchez Escudero L; Guzmán Ramos MI; Aviñó Tarazona V
Anticancer Drugs; 2022 Jan; 33(1):94-99. PubMed ID: 34261922
[TBL] [Abstract][Full Text] [Related]
8. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C
J Clin Oncol; 2020 Nov; 38(33):3925-3936. PubMed ID: 32946353
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Goldberg SB; Gettinger SN; Mahajan A; Chiang AC; Herbst RS; Sznol M; Tsiouris AJ; Cohen J; Vortmeyer A; Jilaveanu L; Yu J; Hegde U; Speaker S; Madura M; Ralabate A; Rivera A; Rowen E; Gerrish H; Yao X; Chiang V; Kluger HM
Lancet Oncol; 2016 Jul; 17(7):976-983. PubMed ID: 27267608
[TBL] [Abstract][Full Text] [Related]
10. Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.
Gibney GT; Atkins MB
J Clin Oncol; 2015 Jun; 33(17):1873-7. PubMed ID: 25964248
[TBL] [Abstract][Full Text] [Related]
11. Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab.
Gracia-Cazaña T; Padgett E; Hernández-García A; Sánchez-Salas MP
Dermatol Online J; 2019 Dec; 25(12):. PubMed ID: 32045170
[TBL] [Abstract][Full Text] [Related]
12. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJ; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Lupinacci R; Krepler C; Ibrahim N; Kicinski M; Marreaud S; van Akkooi AC; Suciu S; Robert C
Eur J Cancer; 2019 Jul; 116():148-157. PubMed ID: 31200321
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
16. Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study.
Shen L; Qi H; Chen S; Cao F; Xie L; Wu Y; Ma W; Song Z; Yuan H; Zhang T; Li D; Wen X; Chen Q; Li W; Zhang X; Fan W
Cancer Immunol Immunother; 2020 Sep; 69(9):1713-1724. PubMed ID: 32333081
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience.
Cimminiello C; Indini A; Di Guardo L; Prisciandaro M; Randon G; Tolomio E; De Braud F; Del Vecchio M
Melanoma Res; 2019 Jun; 29(3):289-294. PubMed ID: 30520799
[TBL] [Abstract][Full Text] [Related]
18. Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab.
Rickard F; Hyams C; Low AT
BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29735504
[TBL] [Abstract][Full Text] [Related]
19. Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
Nardin C; Mateus C; Texier M; Lanoy E; Hibat-Allah S; Ammari S; Robert C; Dhermain F
Melanoma Res; 2018 Apr; 28(2):111-119. PubMed ID: 29356789
[TBL] [Abstract][Full Text] [Related]
20. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
Robert C; Ribas A; Hamid O; Daud A; Wolchok JD; Joshua AM; Hwu WJ; Weber JS; Gangadhar TC; Joseph RW; Dronca R; Patnaik A; Zarour H; Kefford R; Hersey P; Zhang J; Anderson J; Diede SJ; Ebbinghaus S; Hodi FS
J Clin Oncol; 2018 Jun; 36(17):1668-1674. PubMed ID: 29283791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]